Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin

Endocrine. 2012 Dec;42(3):754-5. doi: 10.1007/s12020-012-9677-0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases / complications*
  • Fatty Liver / complications*
  • Humans
  • Insulin Resistance / physiology*
  • Metabolic Syndrome / complications*